Amorfix, Biogen Idec deal

Biogen Idec received an exclusive, worldwide license to Amorfix's disease specific epitopes (DSEs) and mAbs to treat amyotrophic lateral sclerosis (ALS), excluding their use in vaccines and diagnostic...